{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:20:39Z","timestamp":1790396439482,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,7,9]],"date-time":"2014-07-09T00:00:00Z","timestamp":1404864000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2466-14-113","type":"journal-article","created":{"date-parts":[[2014,7,9]],"date-time":"2014-07-09T09:05:35Z","timestamp":1404896735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and safety of fluticasone furoate 100\u00a0\u03bcg and 200\u00a0\u03bcg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study"],"prefix":"10.1186","volume":"14","author":[{"given":"Ashley","family":"Woodcock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"L\u00f6tvall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ellsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Jacques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,9]]},"reference":[{"key":"554_CR1","volume-title":"Global Strategy for Asthma Management and Prevention","author":"Global Initiative for Asthma (GINA)","year":"2012","unstructured":"Global Initiative for Asthma (GINA): Global Strategy for Asthma Management and Prevention. 2012, \n                    http:\/\/www.ginasthma.org\/documents\/5\/documents_variants\/37\n                    \n                  . Date last updated: December 2012. Date last accessed: 23 June 2014"},{"key":"554_CR2","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMra0804579","volume":"360","author":"CH Fanta","year":"2009","unstructured":"Fanta CH: Drug therapy: asthma. N Engl J Med. 2009, 360: 1002-1014. 10.1056\/NEJMra0804579.","journal-title":"N Engl J Med"},{"key":"554_CR3","first-page":"268","volume":"67","author":"LG Heaney","year":"2012","unstructured":"Heaney LG, Horne R: Non-adherence in difficult asthma: time to take it seriously. Chest. 2012, 67: 268-270.","journal-title":"Chest"},{"key":"554_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2466-10-1","volume":"10","author":"D Price","year":"2010","unstructured":"Price D, Robertson A, Bullen K, Rand C, Horne R, Staudinger H: Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med. 2010, 10: 1-10.1186\/1471-2466-10-1.","journal-title":"BMC Pulm Med"},{"key":"554_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4104\/pcrj.2013.00017","volume":"22","author":"D Price","year":"2013","unstructured":"Price D, Lee AJ, Sims EJ, Kemp L, Hillyer EV, Chisholm A, von Ziegenweidt J, Williams A: Characteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort study. Prim Care Respir J. 2013, 22: 161-168. 10.4104\/pcrj.2013.00017.","journal-title":"Prim Care Respir J"},{"key":"554_CR6","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1021\/jm800279t","volume":"51","author":"K Biggadike","year":"2008","unstructured":"Biggadike K, Bledsoe RK, Hassell AM, Kirk BE, McLay IM, Shewchuk LM, Stewart EL: X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J Med Chem. 2008, 51: 3349-3352. 10.1021\/jm800279t.","journal-title":"J Med Chem"},{"key":"554_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ejphar.2011.08.022","volume":"670","author":"C Rossios","year":"2011","unstructured":"Rossios C, To Y, Ito M, Barnes PJ, Adcock IM, Johnson M, Ito K: Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur J Pharmacol. 2011, 670: 244-251. 10.1016\/j.ejphar.2011.08.022.","journal-title":"Eur J Pharmacol"},{"key":"554_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1465-9921-8-54","volume":"8","author":"A Valotis","year":"2007","unstructured":"Valotis A, H\u00f6gger P: Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res. 2007, 8: 54-10.1186\/1465-9921-8-54.","journal-title":"Respir Res"},{"key":"554_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/1465-9921-12-160","volume":"12","author":"A Woodcock","year":"2011","unstructured":"Woodcock A, Bleecker ER, Busse WW, L\u00f6tvall J, Snowise NG, Frith L, Jacques L, Haumann B, Bateman ED: Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respir Res. 2011, 12: 160-10.1186\/1465-9921-12-160.","journal-title":"Respir Res"},{"key":"554_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.anai.2012.08.017","volume":"109","author":"ER Bleecker","year":"2012","unstructured":"Bleecker ER, Bateman ED, Busse WW, Woodcock A, Frith L, House KW, Jacques L, Davis AM, Haumann B, L\u00f6tvall J: Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Ann Allergy Asthma Immunol. 2012, 109: 353-358. 10.1016\/j.anai.2012.08.017. e4","journal-title":"Ann Allergy Asthma Immunol"},{"key":"554_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1136\/thoraxjnl-2011-200308","volume":"67","author":"WW Busse","year":"2012","unstructured":"Busse WW, Bleecker ER, Bateman ED, L\u00f6tvall J, Forth R, Davis AM, Jacques L, Haumann B, Woodcock A: Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax. 2012, 67: 35-41. 10.1136\/thoraxjnl-2011-200308.","journal-title":"Thorax"},{"key":"554_CR12","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1183\/09031936.00064513","volume":"43","author":"PM O\u2019Byrne","year":"2014","unstructured":"O\u2019Byrne PM, Bleecker ER, Bateman ED, Busse WW, Woodcock A, Forth R, Toler WT, Jacques L, L\u00f6tvall J: Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J. 2014, 43: 773-782. 10.1183\/09031936.00064513.","journal-title":"Eur Respir J"},{"key":"554_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.rmed.2013.11.009","volume":"108","author":"J L\u00f6tvall","year":"2014","unstructured":"L\u00f6tvall J, Bleecker ER, Busse WW, O\u2019Byrne PM, Woodcock A, Kerwin EM, Stone S, Forth R, Jacques L, Bateman ED: Efficacy and safety of fluticasone furoate 100 \u03bcg once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomised trial. Respir Med. 2014, 108: 41-49. 10.1016\/j.rmed.2013.11.009.","journal-title":"Respir Med"},{"key":"554_CR14","first-page":"A1298","volume":"183","author":"WW Busse","year":"2011","unstructured":"Busse WW, Bateman ED, Bleecker ER, L\u00f6tvall J, Woodcock A, Forth R, Jacques L, Medley H, Haumann B: Fluticasone furoate (FF), a once-daily inhaled corticosteroid (ICS), is efficacious in patients with uncontrolled asthma across a range of treatment steps. Am J Respir Crit Care Med. 2011, 183: A1298-[abstract]","journal-title":"Am J Respir Crit Care Med"},{"key":"554_CR15","first-page":"024","volume":"6","author":"A Allen","year":"2014","unstructured":"Allen A, Bal J, Moore A, Stone S, Tombs L: Bioequivalence and Dose Proportionality of Inhaled Fluticasone Furoate. J Bioequiv Availab. 2014, 6: 024-032.","journal-title":"J Bioequiv Availab"},{"key":"554_CR16","volume-title":"Guidelines For The Diagnosis And Management Of Asthma \u2013 Expert Panel Report 3","author":"National Institutes for Health (NIH)","year":"2007","unstructured":"National Institutes for Health (NIH): Guidelines For The Diagnosis And Management Of Asthma \u2013 Expert Panel Report 3. 2007, \n                    http:\/\/www.nhlbi.nih.gov\/guidelines\/asthma\/asthgdln.pdf\n                    \n                  . Date last updated: August 2007. Date last accessed: 23 June 2014"},{"key":"554_CR17","unstructured":"WMA Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended (latest) by the 59th WMA General Assembly, Seoul, Korea, October 2008. \n                    http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/index.html\n                    \n                  . Date last updated: October 2008. Date last accessed: 23 June 2014,"},{"key":"554_CR18","unstructured":"International Conference on Harmonisation Tripartite Guideline. Guidance for Good Clinical Practice E6 (R1). \n                    http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6_R1\/Step4\/E6_R1__Guideline.pdf\n                    \n                  . 1996. Date last accessed: 23 June 2014"},{"key":"554_CR19","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","volume":"124","author":"M Schatz","year":"2009","unstructured":"Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P: The minimally important difference of the asthma control test. J Allergy Clin Immunol. 2009, 124: 719-723. 10.1016\/j.jaci.2009.06.053. e1","journal-title":"J Allergy Clin Immunol"},{"key":"554_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","volume":"180","author":"HK Reddel","year":"2009","unstructured":"Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jongste JC, Kerstjens HA, Lazarus SC, Levy ML, O\u2019Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Sullivan SD, Szefler SJ, Thomas MD, Wenzel SE, American Thoracic Society\/European Respiratory Society Task Force on Asthma Control and Exacerbations: An official American Thoracic Society\/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009, 180: 59-99. 10.1164\/rccm.200801-060ST.","journal-title":"Am J Respir Crit Care Med"},{"key":"554_CR21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/crj.12026","volume":"7","author":"A Allen","year":"2013","unstructured":"Allen A, Schenkenberger I, Trivedi R, Cole J, Hicks W, Gul N, Jacques L: Inhaled fluticasone furoate\/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study. Clin Respir J. 2013, 7: 397-406. 10.1111\/crj.12026.","journal-title":"Clin Respir J"},{"key":"554_CR22","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.rmed.2012.01.004","volume":"106","author":"ED Bateman","year":"2012","unstructured":"Bateman ED, Bleecker ER, L\u00f6tvall J, Woodcock A, Forth R, Medley H, Davis AM, Jacques L, Haumann B, Busse WW: Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med. 2012, 106: 642-650. 10.1016\/j.rmed.2012.01.004.","journal-title":"Respir Med"},{"key":"554_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1136\/thoraxjnl-2012-202606","volume":"68","author":"WW Busse","year":"2013","unstructured":"Busse WW, O\u2019Byrne PM, Bleecker ER, L\u00f6tvall J, Woodcock A, Andersen L, Hicks W, Crawford J, Jacques L, Apoux L, Bateman ED: Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial. Thorax. 2013, 68: 513-520. 10.1136\/thoraxjnl-2012-202606.","journal-title":"Thorax"},{"key":"554_CR24","volume-title":"J Allergy Clin Immunol Pract","author":"ER Bleecker","year":"2014","unstructured":"Bleecker ER, L\u00f6tvall J, O\u2019Byrne PM, Woodcock A, Busse WW, Forth R, Medley H, Nunn C, Jacques L, Bateman ED: Fluticasone furoate\/vilanterol 100\/25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. J Allergy Clin Immunol Pract. 2014, ePub ahead of print"},{"key":"554_CR25","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1136\/thx.2006.073429","volume":"62","author":"M Berry","year":"2007","unstructured":"Berry M, Morgan A, Shaw DE, Parker D, Green R, Brightling C, Bradding P, Wardlaw AJ, Pavord ID: Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax. 2007, 62: 1043-1049. 10.1136\/thx.2006.073429.","journal-title":"Thorax"},{"key":"554_CR26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/thx.2010.135574","volume":"67","author":"HL Petsky","year":"2012","unstructured":"Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA, Chang AB: A systematic review and meta analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax. 2012, 67: 199-208. 10.1136\/thx.2010.135574.","journal-title":"Thorax"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2466-14-113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2466-14-113\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2466-14-113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2466-14-113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T23:13:45Z","timestamp":1548198825000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/1471-2466-14-113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,9]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["554"],"URL":"https:\/\/doi.org\/10.1186\/1471-2466-14-113","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,9]]},"assertion":[{"value":"15 January 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"113"}}